Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Leukemia

  Free Subscription


Articles published in Br J Haematol

Retrieve available abstracts of 141 articles:
HTML format
Text format



Single Articles


    December 2017
  1. WOLACH O, Amitai I, DeAngelo DJ
    Current challenges and opportunities in treating adult patients with Philadelphia-negative acute lymphoblastic leukaemia.
    Br J Haematol. 2017;179:705-723.
    PubMed     Text format     Abstract available


  2. PAVIGLIANITI A, Ruggeri A, Volt F, Sanz G, et al
    Evaluation of a disease risk index for adult patients undergoing umbilical cord blood transplantation for haematological malignancies.
    Br J Haematol. 2017;179:790-801.
    PubMed     Text format     Abstract available


  3. KHARFAN-DABAJA MA, Al Malki MM, Deotare U, Raj RV, et al
    Haematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a North American multicentre collaborative study.
    Br J Haematol. 2017;179:781-789.
    PubMed     Text format     Abstract available


    November 2017
  4. KOHNKE T, Wittmann VK, Bucklein VL, Lichtenegger F, et al
    Diagnosis of CLL revisited: increased specificity by a modified five-marker scoring system including CD200.
    Br J Haematol. 2017;179:480-487.
    PubMed     Text format     Abstract available


  5. WU B, Slabicki M, Sellner L, Dietrich S, et al
    MED12 mutations and NOTCH signalling in chronic lymphocytic leukaemia.
    Br J Haematol. 2017;179:421-429.
    PubMed     Text format     Abstract available


  6. CHEN Y, Cheng Y, Suo P, Yan C, et al
    Donor-derived CD19-targeted T cell infusion induces minimal residual disease-negative remission in relapsed B-cell acute lymphoblastic leukaemia with no response to donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantati
    Br J Haematol. 2017;179:598-605.
    PubMed     Text format     Abstract available


  7. IGWE IJ, Yang D, Merchant A, Merin N, et al
    The presence of Philadelphia chromosome does not confer poor prognosis in adult pre-B acute lymphoblastic leukaemia in the tyrosine kinase inhibitor era - a surveillance, epidemiology, and end results database analysis.
    Br J Haematol. 2017;179:618-626.
    PubMed     Text format     Abstract available


  8. DONADIEU J, Beaupain B, Fenneteau O, Bellanne-Chantelot C, et al
    Congenital neutropenia in the era of genomics: classification, diagnosis, and natural history.
    Br J Haematol. 2017;179:557-574.
    PubMed     Text format     Abstract available


  9. MEDINGER M, Passweg JR
    Acute myeloid leukaemia genomics.
    Br J Haematol. 2017;179:530-542.
    PubMed     Text format     Abstract available


    October 2017
  10. HAN LJ, Wang Y, Fan ZP, Huang F, et al
    Haploidentical transplantation compared with matched sibling and unrelated donor transplantation for adults with standard-risk acute lymphoblastic leukaemia in first complete remission.
    Br J Haematol. 2017;179:120-130.
    PubMed     Text format     Abstract available


  11. EWINS K, Malone A, Phelan E, Webb D, et al
    Nelarabine-induced peripheral and central neurotoxicity: can sequential MRI brain imaging help to define its natural history?
    Br J Haematol. 2017;179:294-297.
    PubMed     Text format     Abstract available


  12. STELLRECHT CM, Chen LS, Ayres ML, Dennison JB, et al
    Chlorinated adenosine analogue induces AMPK and autophagy in chronic lymphocytic leukaemia cells during therapy.
    Br J Haematol. 2017;179:266-271.
    PubMed     Text format     Abstract available


  13. EDLINGER L, Berger-Becvar A, Menzl I, Hoermann G, et al
    Expansion of BCR/ABL1+ cells requires PAK2 but not PAK1.
    Br J Haematol. 2017;179:229-241.
    PubMed     Text format     Abstract available


  14. HUGHES TP, Munhoz E, Aurelio Salvino M, Ong TC, et al
    Nilotinib dose-optimization in newly diagnosed chronic myeloid leukaemia in chronic phase: final results from ENESTxtnd.
    Br J Haematol. 2017;179:219-228.
    PubMed     Text format     Abstract available


  15. MO XD, Lv M, Huang XJ
    Preventing relapse after haematopoietic stem cell transplantation for acute leukaemia: the role of post-transplantation minimal residual disease (MRD) monitoring and MRD-directed intervention.
    Br J Haematol. 2017;179:184-197.
    PubMed     Text format     Abstract available


    September 2017
  16. ALVAREZ-LARRAN A, Senin A, Fernandez-Rodriguez C, Pereira A, et al
    Impact of genotype on leukaemic transformation in polycythaemia vera and essential thrombocythaemia.
    Br J Haematol. 2017;178:764-771.
    PubMed     Text format     Abstract available


  17. ZHANG X, Yang L, Liu X, Nie Z, et al
    Research on the epigenetic regulation mechanism of the PTPN6 gene in advanced chronic myeloid leukaemia.
    Br J Haematol. 2017;178:728-738.
    PubMed     Text format     Abstract available


  18. FENAUX P, Muus P, Kantarjian H, Lyons RM, et al
    Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long-term safety and efficacy.
    Br J Haematol. 2017;178:906-913.
    PubMed     Text format     Abstract available


  19. GOCKERITZ E, Vondey V, Guastafierro A, Pizevska M, et al
    Establishing a chemical genetic link between Bruton tyrosine kinase activity in malignant B cells and cell functions involved in the micro-environmental dialogue.
    Br J Haematol. 2017;178:949-953.
    PubMed     Text format     Abstract available


  20. GHAMLOUCH H, Nguyen-Khac F, Bernard OA
    Chronic lymphocytic leukaemia genomics and the precision medicine era.
    Br J Haematol. 2017;178:852-870.
    PubMed     Text format     Abstract available


    August 2017
  21. DUROT E, Tomowiak C, Michallet AS, Dupuis J, et al
    Transformed Waldenstrom macroglobulinaemia: clinical presentation and outcome. A multi-institutional retrospective study of 77 cases from the French Innovative Leukemia Organization (FILO).
    Br J Haematol. 2017 Aug 2. doi: 10.1111/bjh.14881.
    PubMed     Text format     Abstract available


  22. ZWAAN CM, Kowalczyk J, Schmitt C, Bielorai B, et al
    Safety and efficacy of nelarabine in children and young adults with relapsed or refractory T-lineage acute lymphoblastic leukaemia or T-lineage lymphoblastic lymphoma: results of a phase 4 study.
    Br J Haematol. 2017 Aug 2. doi: 10.1111/bjh.14874.
    PubMed     Text format     Abstract available


  23. SCHETELIG J, de Wreede LC, Andersen NS, Moreno C, et al
    Centre characteristics and procedure-related factors have an impact on outcomes of allogeneic transplantation for patients with CLL: a retrospective analysis from the European Society for Blood and Marrow Transplantation (EBMT).
    Br J Haematol. 2017;178:521-533.
    PubMed     Text format     Abstract available


  24. STRATI P, Parikh SA, Chaffee KG, Kay NE, et al
    Relationship between co-morbidities at diagnosis, survival and ultimate cause of death in patients with chronic lymphocytic leukaemia (CLL): a prospective cohort study.
    Br J Haematol. 2017;178:394-402.
    PubMed     Text format     Abstract available


  25. ZELLER B, Glosli H, Forestier E, Ha SY, et al
    Hyperleucocytosis in paediatric acute myeloid leukaemia - the challenge of white blood cell counts above 200 x 109 /l. The NOPHO experience 1984-2014.
    Br J Haematol. 2017;178:448-456.
    PubMed     Text format     Abstract available


  26. KARLSSON L, Forestier E, Hasle H, Jahnukainen K, et al
    Outcome after intensive reinduction therapy and allogeneic stem cell transplant in paediatric relapsed acute myeloid leukaemia.
    Br J Haematol. 2017;178:592-602.
    PubMed     Text format     Abstract available


  27. MESSINA M, Chiaretti S, Fedullo AL, Piciocchi A, et al
    Clinical significance of recurrent copy number aberrations in B-lineage acute lymphoblastic leukaemia without recurrent fusion genes across age cohorts.
    Br J Haematol. 2017;178:583-587.
    PubMed     Text format     Abstract available


  28. EYRE TA, Schuh A
    An update for Richter syndrome - new directions and developments.
    Br J Haematol. 2017;178:508-520.
    PubMed     Text format     Abstract available


    July 2017
  29. CHEN Y, Pourabdollah M, Chang H
    Acute myeloid leukemia with mutated NPM1 demonstrating multilineage dysplasia and marked thrombocytosis.
    Br J Haematol. 2017 Jul 5. doi: 10.1111/bjh.14741.
    PubMed     Text format    


  30. THEUNISSEN PMJ, van den Branden A, Van Der Sluijs-Gelling A, De Haas V, et al
    Understanding the reconstitution of the B-cell compartment in bone marrow and blood after treatment for B-cell precursor acute lymphoblastic leukaemia.
    Br J Haematol. 2017;178:267-278.
    PubMed     Text format     Abstract available


  31. WILLIAMS J, Heppel NH, Britt-Compton B, Grimstead JW, et al
    Telomere length is an independent prognostic marker in MDS but not in de novo AML.
    Br J Haematol. 2017;178:240-249.
    PubMed     Text format     Abstract available


  32. ARAI Y, Kondo T, Shigematsu A, Tanaka J, et al
    Increased non-relapse mortality due to high-dose cytarabine plus CY/TBI in BMT/PBSCT for acute lymphoblastic leukaemia in adults.
    Br J Haematol. 2017;178:106-111.
    PubMed     Text format     Abstract available


  33. MARTINI V, Gattazzo C, Frezzato F, Trimarco V, et al
    Cortactin, a Lyn substrate, is a checkpoint molecule at the intersection of BCR and CXCR4 signalling pathway in chronic lymphocytic leukaemia cells.
    Br J Haematol. 2017;178:81-93.
    PubMed     Text format     Abstract available


  34. THEUNISSEN PMJ, Sedek L, De Haas V, Szczepanski T, et al
    Detailed immunophenotyping of B-cell precursors in regenerating bone marrow of acute lymphoblastic leukaemia patients: implications for minimal residual disease detection.
    Br J Haematol. 2017;178:257-266.
    PubMed     Text format     Abstract available


  35. SOARES M, Saussoy P, Maskens M, Reul H, et al
    Eliminating malignant cells from cryopreserved ovarian tissue is possible in leukaemia patients.
    Br J Haematol. 2017;178:231-239.
    PubMed     Text format     Abstract available


  36. JONES JA, Hillmen P, Coutre S, Tam C, et al
    Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib.
    Br J Haematol. 2017;178:286-291.
    PubMed     Text format     Abstract available


  37. STRATI P, Parikh SA, Chaffee KG, Achenbach SJ, et al
    CD49d associates with nodal presentation and subsequent development of lymphadenopathy in patients with chronic lymphocytic leukaemia.
    Br J Haematol. 2017;178:99-105.
    PubMed     Text format     Abstract available


    June 2017
  38. HO G, Jonas BA, Li Q, Brunson A, et al
    Early mortality and complications in hospitalized adult Californians with acute myeloid leukaemia.
    Br J Haematol. 2017;177:791-799.
    PubMed     Text format     Abstract available


  39. ONIDA F, de Wreede LC, van Biezen A, Eikema DJ, et al
    Allogeneic stem cell transplantation in patients with atypical chronic myeloid leukaemia: a retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.
    Br J Haematol. 2017;177:759-765.
    PubMed     Text format     Abstract available


  40. LIU CY, Hsieh FS, Chu PY, Tsai WC, et al
    Carfilzomib induces leukaemia cell apoptosis via inhibiting ELK1/KIAA1524 (Elk-1/CIP2A) and activating PP2A not related to proteasome inhibition.
    Br J Haematol. 2017;177:726-740.
    PubMed     Text format     Abstract available


  41. KAYASTHA GK, Ranjitkar N, Gurung R, Kc RK, et al
    The use of Imatinib resistance mutation analysis to direct therapy in Philadelphia chromosome/BCR-ABL1 positive chronic myeloid leukaemia patients failing Imatinib treatment, in Patan Hospital, Nepal.
    Br J Haematol. 2017;177:1000-1007.
    PubMed     Text format     Abstract available


  42. CORREA DE ARAUJO KOURY L, Ganser A, Berliner N, Rego EM, et al
    Treating acute promyelocytic leukaemia in Latin America: lessons from the International Consortium on Acute Leukaemia experience.
    Br J Haematol. 2017;177:979-983.
    PubMed     Text format     Abstract available


  43. KAYASTHA GK, Ranjitkar N, Gurung R, Kc RK, et al
    Treating Philadelphia chromosome/BCR-ABL1 positive patients with Glivec (Imatinib mesylate): 10 years' experience at Patan Hospital, Nepal.
    Br J Haematol. 2017;177:991-999.
    PubMed     Text format     Abstract available


    May 2017
  44. TAO L, Clarke CA, Rosenberg AS, Advani RH, et al
    Subsequent primary malignancies after diffuse large B-cell lymphoma in the modern treatment era.
    Br J Haematol. 2017 May 25. doi: 10.1111/bjh.14638.
    PubMed     Text format     Abstract available


  45. EPPERLA N, Pham AQ, Burnette BL, Wiseman GA, et al
    Risk of histological transformation and therapy-related myelodysplasia/acute myeloid leukaemia in patients receiving radioimmunotherapy for follicular lymphoma.
    Br J Haematol. 2017 May 3. doi: 10.1111/bjh.14688.
    PubMed     Text format     Abstract available


  46. SCOTT S, Travis D, Whitby L, Bainbridge J, et al
    Measurement of BCR-ABL1 by RT-qPCR in chronic myeloid leukaemia: findings from an International EQA Programme.
    Br J Haematol. 2017;177:414-422.
    PubMed     Text format     Abstract available


  47. RHEINGOLD SR, Tasian SK, Whitlock JA, Teachey DT, et al
    A phase 1 trial of temsirolimus and intensive re-induction chemotherapy for 2nd or greater relapse of acute lymphoblastic leukaemia: a Children's Oncology Group study (ADVL1114).
    Br J Haematol. 2017;177:467-474.
    PubMed     Text format     Abstract available


  48. THOMPSON PA, Stingo F, Keating MJ, Wierda WG, et al
    Long-term follow-up of patients receiving allogeneic stem cell transplant for chronic lymphocytic leukaemia: mixed T-cell chimerism is associated with high relapse risk and inferior survival.
    Br J Haematol. 2017;177:567-577.
    PubMed     Text format     Abstract available


  49. THOMPSON PA, Ravandi F
    How I manage patients with hairy cell leukaemia.
    Br J Haematol. 2017;177:543-556.
    PubMed     Text format     Abstract available


    April 2017
  50. MARTIN P, Chen Z, Cheson BD, Robinson KS, et al
    Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphoma.
    Br J Haematol. 2017 Apr 17. doi: 10.1111/bjh.14667.
    PubMed     Text format     Abstract available


  51. BULDINI B, Rizzati F, Masetti R, Fagioli F, et al
    Prognostic significance of flow-cytometry evaluation of minimal residual disease in children with acute myeloid leukaemia treated according to the AIEOP-AML 2002/01 study protocol.
    Br J Haematol. 2017;177:116-126.
    PubMed     Text format     Abstract available


  52. ORLOWSKI RJ, Porter DL, Frey NV
    The promise of chimeric antigen receptor T cells (CARTs) in leukaemia.
    Br J Haematol. 2017;177:13-26.
    PubMed     Text format     Abstract available


  53. AKAHANE K, Li Z, Etchin J, Berezovskaya A, et al
    Anti-leukaemic activity of the TYK2 selective inhibitor NDI-031301 in T-cell acute lymphoblastic leukaemia.
    Br J Haematol. 2017;177:271-282.
    PubMed     Text format     Abstract available


    March 2017
  54. MINAMI M, Arita T, Iwasaki H, Muta T, et al
    Comparative analysis of pulmonary hypertension in patients treated with imatinib, nilotinib and dasatinib.
    Br J Haematol. 2017 Mar 24. doi: 10.1111/bjh.14608.
    PubMed     Text format     Abstract available


  55. TASIAN SK, Hunger SP
    Genomic characterization of paediatric acute lymphoblastic leukaemia: an opportunity for precision medicine therapeutics.
    Br J Haematol. 2017;176:867-882.
    PubMed     Text format     Abstract available


    February 2017
  56. SAWAS A, Farber CM, Schreeder MT, Khalil MY, et al
    A phase 1/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab.
    Br J Haematol. 2017 Feb 21. doi: 10.1111/bjh.14534.
    PubMed     Text format     Abstract available


  57. SHARMAN JP, Farber CM, Mahadevan D, Schreeder MT, et al
    Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial.
    Br J Haematol. 2017;176:412-420.
    PubMed     Text format     Abstract available


  58. RINGDEN O, Labopin M, Schmid C, Sadeghi B, et al
    Sequential chemotherapy followed by reduced-intensity conditioning and allogeneic haematopoietic stem cell transplantation in adult patients with relapse or refractory acute myeloid leukaemia: a survey from the Acute Leukaemia Working Party of EBMT.
    Br J Haematol. 2017;176:431-439.
    PubMed     Text format     Abstract available


  59. WAN H, Cai J, Chen F, Zhu J, et al
    SOX12: a novel potential target for acute myeloid leukaemia.
    Br J Haematol. 2017;176:421-430.
    PubMed     Text format     Abstract available


  60. BERTAINA A, Vinti L, Strocchio L, Gaspari S, et al
    The combination of bortezomib with chemotherapy to treat relapsed/refractory acute lymphoblastic leukaemia of childhood.
    Br J Haematol. 2017;176:629-636.
    PubMed     Text format     Abstract available


  61. VARGHESE AM, Howard DR, Pocock C, Rawstron AC, et al
    Eradication of minimal residual disease improves overall and progression-free survival in patients with chronic lymphocytic leukaemia, evidence from NCRN CLL207: a phase II trial assessing alemtuzumab consolidation.
    Br J Haematol. 2017;176:573-582.
    PubMed     Text format     Abstract available


  62. CHANG CK, Zhao YS, Xu F, Guo J, et al
    TP53 mutations predict decitabine-induced complete responses in patients with myelodysplastic syndromes.
    Br J Haematol. 2017;176:600-608.
    PubMed     Text format     Abstract available


  63. ROBAK T, Hellmann A, Kloczko J, Loscertales J, et al
    Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukaemia.
    Br J Haematol. 2017;176:618-628.
    PubMed     Text format     Abstract available


  64. LUBBERT M, Ihorst G, Sander PN, Bogatyreva L, et al
    Elevated fetal haemoglobin is a predictor of better outcome in MDS/AML patients receiving 5-aza-2'-deoxycytidine (Decitabine).
    Br J Haematol. 2017;176:609-617.
    PubMed     Text format     Abstract available


    January 2017
  65. WANQUET A, Birsen R, Bonnet C, Boubaya M, et al
    Management of central nervous system involvement in chronic lymphocytic leukaemia: a retrospective cohort of 30 patients.
    Br J Haematol. 2017;176:37-49.
    PubMed     Text format     Abstract available


  66. BROWN FC, Cifani P, Drill E, He J, et al
    Genomics of primary chemoresistance and remission induction failure in paediatric and adult acute myeloid leukaemia.
    Br J Haematol. 2017;176:86-91.
    PubMed     Text format     Abstract available


  67. SEKIYA Y, Xu Y, Muramatsu H, Okuno Y, et al
    Clinical utility of next-generation sequencing-based minimal residual disease in paediatric B-cell acute lymphoblastic leukaemia.
    Br J Haematol. 2017;176:248-257.
    PubMed     Text format     Abstract available


  68. ZEIDAN AM, Smith BD, Carraway HE, Gojo I, et al
    A phase 2 trial of high dose lenalidomide in patients with relapsed/refractory higher-risk myelodysplastic syndromes and acute myeloid leukaemia with trilineage dysplasia.
    Br J Haematol. 2017;176:241-247.
    PubMed     Text format     Abstract available


  69. HASLE H, Kaspers GJ
    Strategies for reducing the treatment-related physical burden of childhood acute myeloid leukaemia - a review.
    Br J Haematol. 2017;176:168-178.
    PubMed     Text format     Abstract available


  70. FRISHMAN-LEVY L, Izraeli S
    Advances in understanding the pathogenesis of CNS acute lymphoblastic leukaemia and potential for therapy.
    Br J Haematol. 2017;176:157-167.
    PubMed     Text format     Abstract available


    December 2016
  71. LANGE AP, Lima AS, Lucena-Araujo AR, Jacomo RH, et al
    The experience of the International Consortium on Acute Promyelocytic Leukemia in monitoring minimal residual disease in acute promyelocytic leukaemia.
    Br J Haematol. 2016 Dec 26. doi: 10.1111/bjh.14490.
    PubMed     Text format    


    July 2016
  72. DANILOV AV, Lewis LD, Lansigan F, Roudaia L, et al
    A phase I dose-ranging study of bendamustine and rituximab in chronic lymphocytic leukemia patients with comorbidities.
    Br J Haematol. 2016 Jul 5. doi: 10.1111/bjh.14171.
    PubMed     Text format    


    June 2016
  73. GAYNON PS, Sun W
    Oligoclonality and new agent evaluation in acute lymphoblastic leukaemia.
    Br J Haematol. 2016;173:950-7.
    PubMed     Text format     Abstract available


  74. WILLIAMS ME, Hong F, Gascoyne RD, Wagner LI, et al
    Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402.
    Br J Haematol. 2016;173:867-75.
    PubMed     Text format     Abstract available


  75. GIONA F, Moleti ML, De Benedittis D, Santopietro M, et al
    Can chronic myeloid leukaemia in children and adolescents be successfully treated without haematopoietic stem cell transplant? A single centre experience.
    Br J Haematol. 2016;173:749-53.
    PubMed     Text format     Abstract available


  76. ZUNA J, Moericke A, Arens M, Koehler R, et al
    Implications of delayed bone marrow aspirations at the end of treatment induction for risk stratification and outcome in children with acute lymphoblastic leukaemia.
    Br J Haematol. 2016;173:742-8.
    PubMed     Text format     Abstract available


    May 2016
  77. SOVERINI S, De Benedittis C, Mancini M, Martinelli G, et al
    Present and future of molecular monitoring in chronic myeloid leukaemia.
    Br J Haematol. 2016;173:337-49.
    PubMed     Text format     Abstract available


  78. FERRET Y, Caillault A, Sebda S, Duez M, et al
    Multi-loci diagnosis of acute lymphoblastic leukaemia with high-throughput sequencing and bioinformatics analysis.
    Br J Haematol. 2016;173:413-20.
    PubMed     Text format     Abstract available


    April 2016
  79. VAN DYKE DL, Werner L, Rassenti LZ, Neuberg D, et al
    The Dohner fluorescence in situ hybridization prognostic classification of chronic lymphocytic leukaemia (CLL): the CLL Research Consortium experience.
    Br J Haematol. 2016;173:105-13.
    PubMed     Text format     Abstract available


  80. DAVIS Z, Forconi F, Parker A, Gardiner A, et al
    The outcome of Chronic lymphocytic leukaemia patients with 97% IGHV gene identity to germline is distinct from cases with <97% identity and similar to those with 98% identity.
    Br J Haematol. 2016;173:127-36.
    PubMed     Text format     Abstract available


  81. JAIN P, Kantarjian H, Sasaki K, Jabbour E, et al
    Analysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes.
    Br J Haematol. 2016;173:114-26.
    PubMed     Text format     Abstract available


  82. BALLEN KK, Lazarus H
    Cord blood transplant for acute myeloid leukaemia.
    Br J Haematol. 2016;173:25-36.
    PubMed     Text format     Abstract available


  83. JACKSON RK, Irving JA, Veal GJ
    Personalization of dexamethasone therapy in childhood acute lymphoblastic leukaemia.
    Br J Haematol. 2016;173:13-24.
    PubMed     Text format     Abstract available


  84. JIANG X, Zhang L, Zhou D
    Acute promyelocytic leukaemia with promyelocyte count below 20.
    Br J Haematol. 2016;173:11.
    PubMed     Text format    


  85. RIDER TG, Grace RJ, Newman JA
    Autoimmune haemolytic anaemia occurring during ibrutinib therapy for chronic lymphocytic leukaemia.
    Br J Haematol. 2016;173:326-7.
    PubMed     Text format    


  86. DANILOV AV
    Autoimmune haemolytic anaemia occurring during ibrutinib therapy for chronic lymphocytic leukaemia--response to Rider et al.
    Br J Haematol. 2016;173:327-8.
    PubMed     Text format    


  87. LOPEZ C, Bergmann AK, Paul U, Murga Penas EM, et al
    Genes encoding members of the JAK-STAT pathway or epigenetic regulators are recurrently mutated in T-cell prolymphocytic leukaemia.
    Br J Haematol. 2016;173:265-73.
    PubMed     Text format     Abstract available


  88. ABRAHAO R, Keogh RH, Lichtensztajn DY, Marcos-Gragera R, et al
    Predictors of early death and survival among children, adolescents and young adults with acute myeloid leukaemia in California, 1988-2011: a population-based study.
    Br J Haematol. 2016;173:292-302.
    PubMed     Text format     Abstract available


  89. KERSTEN B, Valkering M, Wouters R, van Amerongen R, et al
    CD45RA, a specific marker for leukaemia stem cell sub-populations in acute myeloid leukaemia.
    Br J Haematol. 2016;173:219-35.
    PubMed     Text format     Abstract available


  90. MELO CP, Campos CB, Rodrigues Jde O, Aguirre-Neto JC, et al
    Long non-coding RNAs: biomarkers for acute leukaemia subtypes.
    Br J Haematol. 2016;173:318-20.
    PubMed     Text format    


  91. MCGEHEE E, Rakheja D, Oliver D, Chen W, et al
    The importance of plasma D-2HG measurement in screening for IDH mutations in acute myeloid leukaemia.
    Br J Haematol. 2016;173:323-6.
    PubMed     Text format    


  92. GLANCY E, Siles R
    Monoclonal B-cell lymphocytosis and hypogammaglobulinaemia.
    Br J Haematol. 2016;173:316-7.
    PubMed     Text format    


    March 2016
  93. TAKAHASHI H, Watanabe T, Kinoshita A, Yuza Y, et al
    High event-free survival rate with minimum-dose-anthracycline treatment in childhood acute promyelocytic leukaemia: a nationwide prospective study by the Japanese Paediatric Leukaemia/Lymphoma Study Group.
    Br J Haematol. 2016 Mar 31. doi: 10.1111/bjh.14068.
    PubMed     Text format     Abstract available


  94. BURKHARDT B, Mueller S, Khanam T, Perkins SL, et al
    Current status and future directions of T-lymphoblastic lymphoma in children and adolescents.
    Br J Haematol. 2016 Mar 15. doi: 10.1111/bjh.14017.
    PubMed     Text format     Abstract available


  95. MILES RR, Shah RK, Frazer JK
    Molecular genetics of childhood, adolescent and young adult non-Hodgkin lymphoma.
    Br J Haematol. 2016 Mar 11. doi: 10.1111/bjh.14011.
    PubMed     Text format     Abstract available


  96. GUO RJ, Bahmanyar M, Minden MD, Chang H, et al
    CD33, not early precursor T-cell phenotype, is associated with adverse outcome in adult T-cell acute lymphoblastic leukaemia.
    Br J Haematol. 2016;172:823-5.
    PubMed     Text format    


  97. VAN DER VELDEN VH, de Launaij D, de Vries JF, de Haas V, et al
    New cellular markers at diagnosis are associated with isolated central nervous system relapse in paediatric B-cell precursor acute lymphoblastic leukaemia.
    Br J Haematol. 2016;172:769-81.
    PubMed     Text format     Abstract available


  98. IRVING JA
    Towards an understanding of the biology and targeted treatment of paediatric relapsed acute lymphoblastic leukaemia.
    Br J Haematol. 2016;172:655-66.
    PubMed     Text format     Abstract available


  99. FERNANDES CM, Hamerschlak N, Kishimoto RK, Ratis CA, et al
    Radiotherapy-related acute myeloid leukaemia with KMT2A amplification.
    Br J Haematol. 2016;172:653.
    PubMed     Text format    


  100. HOFBAUER SW, Krenn PW, Pinomicronn Hofbauer J, Pucher S, et al
    The AKT1 isoform plays a dominant role in the survival and chemoresistance of chronic lymphocytic leukaemia cells.
    Br J Haematol. 2016;172:815-9.
    PubMed     Text format    


  101. BERQUET L, Valleron W, Grgurevic S, Quelen C, et al
    Small nucleolar RNA expression profiles refine the prognostic impact of IGHV mutational status on treatment-free survival in chronic lymphocytic leukaemia.
    Br J Haematol. 2016;172:819-23.
    PubMed     Text format    


  102. MAIQUES-DIAZ A, Hernando M, Sanchez-Lopez A, Rio-Machin A, et al
    MAPK8-mediated stabilization of SP1 is essential for RUNX1-RUNX1T1 - driven leukaemia.
    Br J Haematol. 2016;172:807-10.
    PubMed     Text format    


  103. BLECKMANN K, Schrappe M
    Advances in therapy for Philadelphia-positive acute lymphoblastic leukaemia of childhood and adolescence.
    Br J Haematol. 2016;172:855-69.
    PubMed     Text format     Abstract available


  104. MIDDEKE JM, Herold S, Rucker-Braun E, Berdel WE, et al
    TP53 mutation in patients with high-risk acute myeloid leukaemia treated with allogeneic haematopoietic stem cell transplantation.
    Br J Haematol. 2016;172:914-22.
    PubMed     Text format     Abstract available


  105. HINAI AA, Valk PJ
    Review: Aberrant EVI1 expression in acute myeloid leukaemia.
    Br J Haematol. 2016;172:870-8.
    PubMed     Text format     Abstract available


  106. MUNOZ-BALLESTER J, Chen-Liang TH, Hurtado AM, Heras I, et al
    Persistent cytotoxic T lymphocyte expansions after allogeneic haematopoietic stem cell transplantation: kinetics, clinical impact and absence of STAT3 mutations.
    Br J Haematol. 2016;172:937-46.
    PubMed     Text format     Abstract available


  107. IACCARINO L, Ottone T, Divona M, Cicconi L, et al
    Mutations affecting both the rearranged and the unrearranged PML alleles in refractory acute promyelocytic leukaemia.
    Br J Haematol. 2016;172:909-13.
    PubMed     Text format     Abstract available


  108. LO-COCO F, Cicconi L, Breccia M
    Current standard treatment of adult acute promyelocytic leukaemia.
    Br J Haematol. 2016;172:841-54.
    PubMed     Text format     Abstract available


  109. WANG HY, McMahon C, Ali SM, Young LE, et al
    Novel FNDC3B and MECOM fusion and WT1 L378fs* 7 frameshift mutation in an acute myeloid leukaemia patient with cytomorphological and immunophenotypic features reminiscent of acute promyelocytic leukaemia.
    Br J Haematol. 2016;172:987-90.
    PubMed     Text format    


  110. VIOLA S, Traer E, Huan J, Hornick NI, et al
    Alterations in acute myeloid leukaemia bone marrow stromal cell exosome content coincide with gains in tyrosine kinase inhibitor resistance.
    Br J Haematol. 2016;172:983-6.
    PubMed     Text format    


    February 2016
  111. CHANG JE, Havighurst T, Kim K, Eickhoff J, et al
    Bendamustine + rituximab chemoimmunotherapy and maintenance lenalidomide in relapsed, refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma: A Wisconsin Oncology Network Study.
    Br J Haematol. 2016 Feb 23. doi: 10.1111/bjh.13957.
    PubMed     Text format     Abstract available


  112. HOUGH R, Rowntree C, Goulden N, Mitchell C, et al
    Efficacy and toxicity of a paediatric protocol in teenagers and young adults with Philadelphia chromosome negative acute lymphoblastic leukaemia: results from UKALL 2003.
    Br J Haematol. 2016;172:439-51.
    PubMed     Text format     Abstract available


  113. DEL GIUDICE I, Marinelli M, Wang J, Bonina S, et al
    Inter- and intra-patient clonal and subclonal heterogeneity of chronic lymphocytic leukaemia: evidences from circulating and lymph nodal compartments.
    Br J Haematol. 2016;172:371-83.
    PubMed     Text format     Abstract available


  114. NIAVARANI A, Herold T, Reyal Y, Sauerland MC, et al
    A 4-gene expression score associated with high levels of Wilms Tumor-1 (WT1) expression is an adverse prognostic factor in acute myeloid leukaemia.
    Br J Haematol. 2016;172:401-11.
    PubMed     Text format     Abstract available


  115. KURTOVIC-KOZARIC A, Hasic A, Radich JP, Bijedic V, et al
    The reality of cancer treatment in a developing country: the effects of delayed TKI treatment on survival, cytogenetic and molecular responses in chronic myeloid leukaemia patients.
    Br J Haematol. 2016;172:420-7.
    PubMed     Text format     Abstract available


  116. RAVANDI F, Jorgensen JL, O'Brien SM, Jabbour E, et al
    Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia.
    Br J Haematol. 2016;172:392-400.
    PubMed     Text format     Abstract available


  117. DE BRAEKELEER M, Gueganic N, Tous C, Le Bris MJ, et al
    Translocations involving 13q14 without associated deletion in chronic lymphoid leukaemia target DLEU2.
    Br J Haematol. 2016;172:467-9.
    PubMed     Text format    


  118. DICKSON GJ, Bustraan S, Hills RK, Ali A, et al
    The value of molecular stratification for CEBPA(DM) and NPM1(MUT) FLT3(WT) genotypes in older patients with acute myeloid leukaemia.
    Br J Haematol. 2016;172:573-80.
    PubMed     Text format     Abstract available


  119. AL MALKI MM, Song JY
    Strongyloides hyperinfection syndrome following haematopoietic stem cell transplantation.
    Br J Haematol. 2016;172:496.
    PubMed     Text format    


  120. DEVILLIER R, Raffoux E, Rey J, Lengline E, et al
    Combination therapy with ruxolitinib plus intensive treatment strategy is feasible in patients with blast-phase myeloproliferative neoplasms.
    Br J Haematol. 2016;172:628-30.
    PubMed     Text format    


    January 2016
  121. MAWAD R, Becker PS, Hendrie P, Scott B, et al
    Phase II study of tosedostat with cytarabine or decitabine in newly diagnosed older patients with acute myeloid leukaemia or high-risk MDS.
    Br J Haematol. 2016;172:238-45.
    PubMed     Text format     Abstract available


  122. ELSE M, Wade R, Oscier D, Catovsky D, et al
    The long-term outcome of patients in the LRF CLL4 trial: the effect of salvage treatment and biological markers in those surviving 10 years.
    Br J Haematol. 2016;172:228-37.
    PubMed     Text format     Abstract available


  123. MACCHIA G, Lonoce A, Venuto S, Macri E, et al
    A rare but recurrent t(8;13)(q24;q14) translocation in B-cell chronic lymphocytic leukaemia causing MYC up-regulation and concomitant loss of PVT1, miR-15/16 and DLEU7.
    Br J Haematol. 2016;172:296-9.
    PubMed     Text format    


  124. BAUMANN T, Delgado J, Santacruz R, Martinez-Trillos A, et al
    CD49d (ITGA4) expression is a predictor of time to first treatment in patients with chronic lymphocytic leukaemia and mutated IGHV status.
    Br J Haematol. 2016;172:48-55.
    PubMed     Text format     Abstract available


  125. BRUMMENDORF TH, Cortes JE, Khoury HJ, Kantarjian HM, et al
    Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib.
    Br J Haematol. 2016;172:97-110.
    PubMed     Text format     Abstract available


  126. LOEB KR, Cherian S, Becker PS, Walter RB, et al
    Comparative analysis of flow cytometry and morphology for the detection of acute myeloid leukaemia cells in cerebrospinal fluid.
    Br J Haematol. 2016;172:134-6.
    PubMed     Text format    


  127. APOLLONIO B, Ramsay AG
    Subclonal heterogeneity in chronic lymphocytic leukaemia: revealing the importance of the lymphoid tumour microenvironment.
    Br J Haematol. 2016;172:7-8.
    PubMed     Text format    


    December 2015
  128. SHIBA N, Ohki K, Kobayashi T, Hara Y, et al
    High PRDM16 expression identifies a prognostic subgroup of pediatric acute myeloid leukaemia correlated to FLT3-ITD, KMT2A-PTD, and NUP98-NSD1: the results of the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 trial.
    Br J Haematol. 2015 Dec 18. doi: 10.1111/bjh.13869.
    PubMed     Text format     Abstract available


  129. CHIHARA D, Cheah CY, Westin JR, Fayad LE, et al
    Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center.
    Br J Haematol. 2015 Dec 9. doi: 10.1111/bjh.13796.
    PubMed     Text format     Abstract available


    November 2015
  130. PREBET T, Sun Z, Ketterling RP, Zeidan A, et al
    Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study.
    Br J Haematol. 2015 Nov 18. doi: 10.1111/bjh.13832.
    PubMed     Text format     Abstract available


  131. BAIN BJ, Ahmad S
    Chronic neutrophilic leukaemia and plasma cell-related neutrophilic leukaemoid reactions.
    Br J Haematol. 2015;171:400-10.
    PubMed     Text format     Abstract available


  132. LOKIREDDY P, Bloxam D, Hodson A, Whalley I, et al
    Extramedullary acute myeloid leukaemia: isolated leukaemic pleural and pericardial effusions without marrow disease.
    Br J Haematol. 2015;171:295.
    PubMed     Text format    


  133. ZHONG H, Chen G, Jukofsky L, Geho D, et al
    MDM2 antagonist clinical response association with a gene expression signature in acute myeloid leukaemia.
    Br J Haematol. 2015;171:432-5.
    PubMed     Text format    


  134. DINMOHAMED AG, Brink M, Visser O, Sonneveld P, et al
    Trends in incidence, primary treatment and survival in chronic myelomonocytic leukaemia: a population-based study of 1359 patients diagnosed in the Netherlands from 1989 to 2012.
    Br J Haematol. 2015;171:436-9.
    PubMed     Text format    


    October 2015
  135. AWASTHI A, Ayello J, Van de Ven C, Elmacken M, et al
    Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20 rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic leukae
    Br J Haematol. 2015 Oct 16. doi: 10.1111/bjh.13764.
    PubMed     Text format     Abstract available


  136. WATTS JM, Kishtagari A, Hsu M, Lacouture ME, et al
    Melanoma and non-melanoma skin cancers in hairy cell leukaemia: a Surveillance, Epidemiology and End Results population analysis and the 30-year experience at Memorial Sloan Kettering Cancer Center.
    Br J Haematol. 2015;171:84-90.
    PubMed     Text format     Abstract available


  137. VAN LAAR M, Kinsey SE, Feltbower RG
    Survival of childhood acute lymphoid leukaemia in Yorkshire by clinical trial era, 1990-2011.
    Br J Haematol. 2015;171:116-9.
    PubMed     Text format     Abstract available


  138. TANAKA Y, Kato M, Hasegawa D, Urayama KY, et al
    Susceptibility to 6-MP toxicity conferred by a NUDT15 variant in Japanese children with acute lymphoblastic leukaemia.
    Br J Haematol. 2015;171:109-15.
    PubMed     Text format     Abstract available


  139. DI GIACOMO D, La Starza R, Barba G, Pierini V, et al
    4q12 translocations with GSX2 expression identify a CD7(+) acute myeloid leukaemia subset.
    Br J Haematol. 2015;171:141-5.
    PubMed     Text format    


    September 2015
  140. DOCHERTY SM, Reza M, Turner G, Bowles K, et al
    Resolution of Roth spots in chronic myeloid leukaemia after treatment with imatinib.
    Br J Haematol. 2015;170:744.
    PubMed     Text format    


  141. OLSSON L, Ivanov Ofverholm I, Noren-Nystrom U, Zachariadis V, et al
    The clinical impact of IKZF1 deletions in paediatric B-cell precursor acute lymphoblastic leukaemia is independent of minimal residual disease stratification in Nordic Society for Paediatric Haematology and Oncology treatment protocols used between 19
    Br J Haematol. 2015;170:847-58.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: